Abstract | BACKGROUND: OBJECTIVE: METHODS: A multicenter controlled randomized double-blind clinical trial was conducted in patients with axillary or palmar-axillary hyperhidrosis defined by a sweat production >50 mg/5 min. Patients received 3 × 50 mg MB daily or placebo over a period of 28 ± 1 days. Main outcome criterion was the reduction of sweat as measured by gravimetry on day 28 ± 1. Quality of life was assessed by Dermatology Life Quality Index (DLQI) and Hyperhidrosis Disease Severity Score (HDSS). RESULTS: A total of 339 patients were randomly assigned to receive MB or placebo. On day 28 ± 1, the mean axillary sweat production was 99 mg for MB and 130 mg for placebo compared with 168 mg and 161 mg respectively at baseline (P = 0.004). Patient's HDSS score decreased in the MB group from 3.2 to 2.4 compared with 3.2 to 2.7 for placebo (P = 0.002). Similar results could be obtained for the DLQI with 9.7 for MB and 12.2 for placebo, which decreased from 16.4 or 17 respectively (P = 0.003). Tolerability was good for both groups. The most frequent adverse event was dry mouth. CONCLUSION:
|
Authors | C Müller, A Berensmeier, H Hamm, T Dirschka, K Reich, T Fischer, B Rzany |
Journal | Journal of the European Academy of Dermatology and Venereology : JEADV
(J Eur Acad Dermatol Venereol)
Vol. 27
Issue 10
Pg. 1278-84
(Oct 2013)
ISSN: 1468-3083 [Electronic] England |
PMID | 23004926
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology. |
Chemical References |
- Quaternary Ammonium Compounds
- Methantheline
|
Topics |
- Adolescent
- Adult
- Aged
- Axilla
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Hyperhidrosis
(drug therapy, metabolism)
- Male
- Methantheline
- Middle Aged
- Palmar Plate
- Quality of Life
- Quaternary Ammonium Compounds
(adverse effects, therapeutic use)
- Severity of Illness Index
- Sweat
(metabolism)
- Treatment Outcome
- Young Adult
|